Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IGM Biosciences ( (IGMS) ) just unveiled an announcement.
On July 1, 2025, IGM Biosciences announced a merger agreement with Concentra Biosciences, where Concentra will acquire IGM Biosciences for $1.247 per share in cash, plus a contingent value right. The transaction, expected to close in August 2025, is subject to conditions including a tender offer for outstanding shares and a minimum cash requirement. The merger aims to benefit IGM Biosciences’ stockholders and positions the company as a wholly owned subsidiary of Concentra.
The most recent analyst rating on (IGMS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on IGM Biosciences stock, see the IGMS Stock Forecast page.
Spark’s Take on IGMS Stock
According to Spark, TipRanks’ AI Analyst, IGMS is a Underperform.
IGM Biosciences’ overall stock score reflects major financial and operational challenges, highlighted by negative corporate events and bearish technical indicators. While valuation offers slight neutrality, the financial instability and compliance risks underpin a low score.
To see Spark’s full report on IGMS stock, click here.
More about IGM Biosciences
IGM Biosciences is a biotechnology company focused on developing engineered IgM-based therapeutic antibodies.
Average Trading Volume: 211,669
Technical Sentiment Signal: Sell
Current Market Cap: $64.92M
Learn more about IGMS stock on TipRanks’ Stock Analysis page.